BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lucarini L, Pini A, Gerace E, Pellicciari R, Masini E, Moroni F. Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling. J Cell Mol Med. 2014;18:468-479. [PMID: 24444146 DOI: 10.1111/jcmm.12197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Rao PD, Sankrityayan H, Srivastava A, Kulkarni YA, Mulay SR, Gaikwad AB. ‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors. Drug Discovery Today 2020;25:1253-61. [DOI: 10.1016/j.drudis.2020.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol 2021;162:496-505. [PMID: 34023129 DOI: 10.1016/j.ygyno.2021.05.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lucarini L, Durante M, Lanzi C, Pini A, Boccalini G, Calosi L, Moroni F, Masini E, Mannaioni G. HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway. J Cell Mol Med 2017;21:324-35. [PMID: 27704718 DOI: 10.1111/jcmm.12967] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
4 Zaffini R, Di Paola R, Cuzzocrea S, Menegazzi M. PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma. Naunyn Schmiedebergs Arch Pharmacol 2016;389:1301-13. [PMID: 27604227 DOI: 10.1007/s00210-016-1294-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sethi GS, Sharma S, Naura AS. PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice. IUBMB Life 2019;71:1003-13. [PMID: 30964965 DOI: 10.1002/iub.2048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Marchand JR, Carotti A, Passeri D, Filipponi P, Liscio P, Camaioni E, Pellicciari R, Gioiello A, Macchiarulo A. Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy. Biochim Biophys Acta 2014;1844:1765-72. [PMID: 25062913 DOI: 10.1016/j.bbapap.2014.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
7 . The all-purpose guinea pig. Lab Anim (NY) 2014;43:79. [PMID: 24552906 DOI: 10.1038/laban.486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Ghonim MA, Pyakurel K, Ibba SV, Wang J, Rodriguez P, Al-Khami AA, Lammi MR, Kim H, Zea AH, Davis C, Okpechi S, Wyczechowska D, Al-Ghareeb K, Mansy MS, Ochoa A, Naura AS, Boulares AH. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci (Lond) 2015;129:951-62. [PMID: 26205779 DOI: 10.1042/CS20150122] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
9 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20:e15-28. [PMID: 30614472 DOI: 10.1016/S1470-2045(18)30786-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 45] [Article Influence: 43.5] [Reference Citation Analysis]
10 Sethi GS, Dharwal V, Naura AS. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol 2017;8:1172. [PMID: 28974953 DOI: 10.3389/fimmu.2017.01172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
11 Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncol Res 2017;25:1441-51. [PMID: 28429680 DOI: 10.3727/096504017X14926854178616] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Zhu LY, Ni ZH, Luo XM, Wang XB. Advance of antioxidants in asthma treatment. World J Respirol 2017; 7(1): 17-28 [DOI: 10.5320/wjr.v7.i1.17] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
13 Durante M, Sgambellone S, Lanzi C, Nardini P, Pini A, Moroni F, Masini E, Lucarini L. Effects of PARP-1 Deficiency and Histamine H4 Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice. Front Pharmacol 2019;10:525. [PMID: 31164820 DOI: 10.3389/fphar.2019.00525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
14 Checa J, Aran JM. Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. Int J Mol Sci 2020;21:E9317. [PMID: 33297418 DOI: 10.3390/ijms21239317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zaffini R, Gotte G, Menegazzi M. Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach. Drug Des Devel Ther 2018;12:281-93. [PMID: 29483769 DOI: 10.2147/DDDT.S150846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Ghonim MA, Pyakurel K, Ibba SV, Al-Khami AA, Wang J, Rodriguez P, Rady HF, El-Bahrawy AH, Lammi MR, Mansy MS, Al-Ghareeb K, Ramsay A, Ochoa A, Naura AS, Boulares AH. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med 2015;13:225. [PMID: 26169874 DOI: 10.1186/s12967-015-0583-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
17 Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. Cell Tissue Res 2017;367:551-69. [PMID: 28190087 DOI: 10.1007/s00441-016-2566-8] [Cited by in Crossref: 140] [Cited by in F6Publishing: 139] [Article Influence: 28.0] [Reference Citation Analysis]
18 Szabo C, Martins V, Liaudet L. Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept. Am J Respir Cell Mol Biol 2020;63:571-90. [PMID: 32640172 DOI: 10.1165/rcmb.2020-0188TR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zakaria EM, El-bassossy HM, El-maraghy NN, Ahmed AF, Ali AA. PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals. European Journal of Pharmacology 2016;791:444-54. [DOI: 10.1016/j.ejphar.2016.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]